0001209191-23-004341.txt : 20230120
0001209191-23-004341.hdr.sgml : 20230120
20230120193946
ACCESSION NUMBER: 0001209191-23-004341
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230119
FILED AS OF DATE: 20230120
DATE AS OF CHANGE: 20230120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Curran Terrie
CENTRAL INDEX KEY: 0001690298
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39094
FILM NUMBER: 23542290
MAIL ADDRESS:
STREET 1: C/O MYOVANT SCIENCES INC.
STREET 2: 320 WEST 37TH STREET, 5TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001783183
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824151574
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
BUSINESS PHONE: (877) 742-8466
MAIL ADDRESS:
STREET 1: 100 CAMPUS DRIVE,
STREET 2: SUITE 102
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-19
0
0001783183
Phathom Pharmaceuticals, Inc.
PHAT
0001690298
Curran Terrie
C/O PHATHOM PHARMACEUTICALS, INC.
100 CAMPUS DRIVE, SUITE 102
FLORHAM PARK
NJ
07932
1
1
0
0
President and Chief Executive
Common Stock
2023-01-19
4
A
0
97500
0.00
A
182628
D
Common Stock
2023-01-20
4
S
0
5821
8.1995
D
176807
D
Common Stock
2235.9
I
by 401(k)
Stock Option (Right to Buy)
8.35
2023-01-19
4
A
0
162500
0.00
A
2033-01-18
Common Stock
162500
162500
D
Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Includes 1,408 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023.
Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.16 to $8.20. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.
/s/ Larry Miller, Attorney-in-Fact for Terrie Curran
2023-01-20